Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRando Segura, Ariadna
dc.contributor.authorUbeda, Maria
dc.contributor.authorValls, Imma
dc.contributor.authorVentosa, Carla
dc.contributor.authorGarcía Hernandez, Nuria
dc.contributor.authorRomero Vico, judit
dc.contributor.authorVargas-Accarino, Elena
dc.contributor.authorPalom, Adriana
dc.contributor.authorRuiz Cobo, Juan Carlos
dc.contributor.authorButi Ferret, Maria
dc.date.accessioned2025-11-25T12:10:11Z
dc.date.available2025-11-25T12:10:11Z
dc.date.issued2025-10
dc.identifier.citationVargas-Accarino E, Rando-Segura A, Úbeda MA, Valls I, Ventosa C, García N, et al. Beyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care. Liver Int. 2025 Oct;45(10):e70330.
dc.identifier.issn1478-3231
dc.identifier.urihttp://hdl.handle.net/11351/14102
dc.descriptionhepatitis B; hepatitis C; Primary care
dc.description.abstractIntroduction Most international guidelines recommend screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) only for individuals with risk factors or elevated ALT levels. However, this approach may not suffice to eradicate viral hepatitis. This study evaluates the application of EASL HBV and HCV screening guidelines in primary care centres (PCCs). Methods The study included two components: (1) A retrospective review (January 2021–March 2023) of microbiology data to determine testing rates, analyse clinical characteristics, and assess management; and (2) A prospective intervention (March–April 2024) involving HBV and HCV screening and risk factor surveys for all adults attending two PCCs for blood collection. Results In the retrospective analysis of 90 170 patients, HBV and HCV screening rates were 16% and 10%, respectively. Among HBsAg-positive patients (n = 84 (0.5%)), 67% lacked risk factors or elevated ALT. Among anti-HCV-positive (n = 277 (3%)) and HCV RNA-positive (n = 45 (0.5%)) patients, 54% and 46% respectively lacked these indicators. In the prospective study of 1030 patients (mean age 55, 39.6% men, 73% Spanish), anti-HCV was detected in 1.16% of cases (HCV RNA in 0.19%). Of these, 67% lacked risk factors or elevated ALT. No HBsAg-positive cases were identified, and hepatitis B vaccination status was uncertain for 50% of patients. Conclusion Risk factor-based screening for HBV and HCV in primary care is a suboptimal approach. More than half of the patients testing positive lacked identifiable risk factors or elevated ALT levels. Universal one-time screening for all adults could address these limitations and significantly advance viral hepatitis elimination efforts.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesLiver International;45(10)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectHepatitis B - Diagnòstic
dc.subjectHepatitis C - Diagnòstic
dc.subjectHepatitis C - Factors de risc
dc.subjectHepatitis B - Factors de risc
dc.subjectCribatge (Medicina)
dc.subject.meshRisk Factors
dc.subject.meshHepatitis B
dc.subject.meshHepatitis C
dc.subject.meshMass Screening
dc.titleBeyond Risk Factors: Rethinking Hepatitis B and Hepatitis C Screening in Primary Care
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1111/liv.70330
dc.subject.decsfactores de riesgo
dc.subject.decshepatitis B
dc.subject.decshepatitis C
dc.subject.decscribado sistemático
dc.relation.publishversionhttps://doi.org/10.1111/liv.70330
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Vargas-Accarino E] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. [Rando-Segura A] CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Úbeda MA] CAP Horta, Barcelona, Spain. [Valls I] CAP San Rafael, Barcelona, Spain. [Ventosa C] CAP Guineueta, Barcelona, Spain. [García N] CAP Río de Janeiro, Barcelona, Spain. [Palom A] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. [Romero-Vico J] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ruiz-Cobo JC, Buti M] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid40970664
dc.identifier.wos001574521600001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI23%2F01065
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record